PROMETHEUS BIOSCIENCES INC (RXDX) Fundamental Analysis & Valuation

NASDAQ:RXDX • US74349U1088

Current stock price

199.92 USD
+0.18 (+0.09%)
At close:
199.95 USD
+0.03 (+0.02%)
After Hours:

This RXDX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. RXDX Profitability Analysis

1.1 Basic Checks

  • In the past year RXDX has reported negative net income.
  • RXDX had a negative operating cash flow in the past year.
RXDX Yearly Net Income VS EBIT VS OCF VS FCFRXDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -50M -100M

1.2 Ratios

  • The profitability ratios for RXDX are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RXDX Yearly ROA, ROE, ROICRXDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 -100 -200 -300 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for RXDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RXDX Yearly Profit, Operating, Gross MarginsRXDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. RXDX Health Analysis

2.1 Basic Checks

  • RXDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • RXDX has more shares outstanding than it did 1 year ago.
  • RXDX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RXDX Yearly Shares OutstandingRXDX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 10M 20M 30M 40M
RXDX Yearly Total Debt VS Total AssetsRXDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 94.07 indicates that RXDX is not in any danger for bankruptcy at the moment.
  • RXDX has a better Altman-Z score (94.07) than 99.20% of its industry peers.
  • There is no outstanding debt for RXDX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 94.07
ROIC/WACCN/A
WACC8.62%
RXDX Yearly LT Debt VS Equity VS FCFRXDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 37.56 indicates that RXDX has no problem at all paying its short term obligations.
  • RXDX has a better Current ratio (37.56) than 98.56% of its industry peers.
  • A Quick Ratio of 37.56 indicates that RXDX has no problem at all paying its short term obligations.
  • RXDX has a Quick ratio of 37.56. This is amongst the best in the industry. RXDX outperforms 98.56% of its industry peers.
Industry RankSector Rank
Current Ratio 37.56
Quick Ratio 37.56
RXDX Yearly Current Assets VS Current LiabilitesRXDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. RXDX Growth Analysis

3.1 Past

  • RXDX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -26.62%.
  • Looking at the last year, RXDX shows a very negative growth in Revenue. The Revenue has decreased by -36.47% in the last year.
  • The Revenue has been growing by 82.51% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-26.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.88%
Revenue 1Y (TTM)-36.47%
Revenue growth 3Y82.51%
Revenue growth 5YN/A
Sales Q2Q%-71.8%

3.2 Future

  • The Earnings Per Share is expected to grow by 22.32% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, RXDX will show a very strong growth in Revenue. The Revenue will grow by 145.93% on average per year.
EPS Next Y-16.9%
EPS Next 2Y-15.66%
EPS Next 3Y-15.77%
EPS Next 5Y22.32%
Revenue Next Year-69.44%
Revenue Next 2Y-47.62%
Revenue Next 3Y136.24%
Revenue Next 5Y145.93%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RXDX Yearly Revenue VS EstimatesRXDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B 2.5B
RXDX Yearly EPS VS EstimatesRXDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

0

4. RXDX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RXDX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RXDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RXDX Price Earnings VS Forward Price EarningsRXDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RXDX Per share dataRXDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • RXDX's earnings are expected to decrease with -15.77% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.66%
EPS Next 3Y-15.77%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RXDX Dividend Analysis

5.1 Amount

  • No dividends for RXDX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

RXDX Fundamentals: All Metrics, Ratios and Statistics

PROMETHEUS BIOSCIENCES INC

NASDAQ:RXDX (6/15/2023, 8:23:19 PM)

After market: 199.95 +0.03 (+0.02%)

199.92

+0.18 (+0.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09
Earnings (Next)N/A
Inst Owners0.05%
Inst Owner Change0%
Ins Owners24.07%
Ins Owner Change0%
Market Cap9.56B
Revenue(TTM)4.00M
Net Income(TTM)-150.56M
Analysts72
Price Target198.9 (-0.51%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.83%
Min EPS beat(2)4.21%
Max EPS beat(2)7.45%
EPS beat(4)4
Avg EPS beat(4)5.45%
Min EPS beat(4)2.44%
Max EPS beat(4)7.69%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)62.01%
Min Revenue beat(2)10.55%
Max Revenue beat(2)113.47%
Revenue beat(4)4
Avg Revenue beat(4)78.91%
Min Revenue beat(4)10.55%
Max Revenue beat(4)143.73%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)22.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.23%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.65%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)9.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2392.69
P/FCF N/A
P/OCF N/A
P/B 13.7
P/tB 13.7
EV/EBITDA N/A
EPS(TTM)-3.52
EYN/A
EPS(NY)-4.66
Fwd EYN/A
FCF(TTM)-2.84
FCFYN/A
OCF(TTM)-2.79
OCFYN/A
SpS0.08
BVpS14.59
TBVpS14.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 293.94%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 37.56
Quick Ratio 37.56
Altman-Z 94.07
F-Score3
WACC8.62%
ROIC/WACCN/A
Cap/Depr(3y)350.62%
Cap/Depr(5y)510.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-26.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.88%
EPS Next Y-16.9%
EPS Next 2Y-15.66%
EPS Next 3Y-15.77%
EPS Next 5Y22.32%
Revenue 1Y (TTM)-36.47%
Revenue growth 3Y82.51%
Revenue growth 5YN/A
Sales Q2Q%-71.8%
Revenue Next Year-69.44%
Revenue Next 2Y-47.62%
Revenue Next 3Y136.24%
Revenue Next 5Y145.93%
EBIT growth 1Y-50.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-36.98%
EBIT Next 3Y-23.62%
EBIT Next 5Y28.62%
FCF growth 1Y-94.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-94.09%
OCF growth 3YN/A
OCF growth 5YN/A

PROMETHEUS BIOSCIENCES INC / RXDX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for PROMETHEUS BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 4 / 10 to RXDX.


What is the valuation status for RXDX stock?

ChartMill assigns a valuation rating of 0 / 10 to PROMETHEUS BIOSCIENCES INC (RXDX). This can be considered as Overvalued.


Can you provide the profitability details for PROMETHEUS BIOSCIENCES INC?

PROMETHEUS BIOSCIENCES INC (RXDX) has a profitability rating of 1 / 10.


What is the financial health of PROMETHEUS BIOSCIENCES INC (RXDX) stock?

The financial health rating of PROMETHEUS BIOSCIENCES INC (RXDX) is 8 / 10.


What is the expected EPS growth for PROMETHEUS BIOSCIENCES INC (RXDX) stock?

The Earnings per Share (EPS) of PROMETHEUS BIOSCIENCES INC (RXDX) is expected to decline by -16.9% in the next year.